Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
79 hedge funds and large institutions have $77M invested in Concert Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 26 closing their positions.
43% more call options, than puts
Call options by funds: $230K | Put options by funds: $161K
13% less funds holding
Funds holding: 91 → 79 (-12)
25% less capital invested
Capital invested by funds: $103M → $77M (-$26.3M)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
46% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.23M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$1.16M |
| 3 |
Millennium Management
New York
|
+$1.16M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$942K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$687K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.01M |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
-$1.71M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.67M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.39M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$956K |
CNCE Hedge Fund Activity: Q2 2021 in Review
79 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2021, worth a combined $77M — down 25% from $103M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CNCE and 14 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 23 added.
The largest buyer was Morgan Stanley, adding an estimated $1.23M. The largest seller was BlackRock, cutting an estimated $7.01M.
- 79 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2021, down from 91 in Q1 2021.
- Funds reported $77M of Concert Pharmaceuticals, Inc. stock for Q2 2021, down 25% quarter-over-quarter.
- 14 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2021 and 26 closed out, a net change of -12 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2021 was Morgan Stanley, an estimated $1.23M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2021 was BlackRock, an estimated $7.01M sold.
Based on aggregated 13F filings for Q2 2021.